Hainan Aike Pharmaceutical Co., Ltd. was established in 2002. After 20 years of ups and downs and tenacious struggle, it has developed into a company that integrates production Research and development、 A modern pharmaceutical production enterprise that integrates sales. The company's core product line is antibiotics, with injection as the main dosage form. It now has GMP products such as glass bottle infusion, non PVC soft bag infusion, small volume injection, medical flushing solution, emulsion, etc line。 The company's non PVC film infusion fully automatic bag making and sealing production line integrates high-pressure filling, precise measurement, pressure sensing and automatic alarm, automatic heating and capping, online cleaning, sterilization, precise positioning of servo motors, precise control of encoders, automatic detection and precise feedback, and other functions. It is at the leading level in China, with an annual production capacity of 100 million bags/bottles of water needles/emulsions/infusion solutions. The first and second phases of the company cover a total area of 130Mu. The main product is the new drug "Etimicin" with independent intellectual property rights sulfate sodium chloride Injection (Aiyi) "And" Moxifloxacin Hydrochloride and Sodium Chloride Injection ". The company provides etimicin sulfate and sodium chloride injection (trade name: The original manufacturer of Aiyi has been producing since 2003 and currently has three specifications: 0.1g, 0.15g, and 0.3g. There are two packaging forms: glass bottles and five layer co extruded infusion film bags. This variety has been listed as a key science and technology project in Haikou City, a national torch plan, and a high-tech project in Hainan Province. In 2019, it won the second prize of Rongying National Science and Technology Progress Award. At present， The company has occupied 80% of the national market share of etimicin infusion and is the preferred aminoglycoside antibiotic in clinical hospitals nationwide. Moxifloxacin is the latest fourth generation quinolone antibiotic, along with levofloxacin The third generation and the fourth generation of enrofloxacin are collectively known as "respiratory quinolones", especially effective against highly drug-resistant Streptococcus pneumoniae. They are recommended by authoritative medical guidelines both domestically and internationally as the preferred drugs for various diseases such as community-acquired pneumonia. Our company's injection of moxifloxacin hydrochloride and sodium chloride is selected as the third batch of national procurement products (only 2Home in the country). In 2021, it ranked first in sales nationwide, and in 2023, its sales reached 3100 million yuan， Listed as a national production reserve variety by four departments including the Ministry of Industry and Information Technology. Our company has won the second prize of National Science and Technology Progress Award Haikou city science and technology progress second prize、 Honorary titles such as Hainan Province High tech Enterprise and Hainan Province "Specialty" Small and Medium sized Enterprise. The production of etimicin sulfate sodium chloride injection and moxifloxacin hydrochloride sodium chloride injection under its umbrella has won various honors such as Hainan Province High tech Products, National Torch Plan Projects, and Hainan Province High tech Projects. The company currently has nearly 30 varieties under development, and multiple national level original new drugs are in the process of research and development. In the next 3 years, multiple innovative drugs with independent patents will be launched. Company current employee200People， Having 60 professionals with various professional and technical titles -person， Among them, there are 2 people with senior professional titles, 14 people with intermediate professional titles, and 51 people with bachelor's degrees or above. The talent strategy has injected strong latecomer power into the company's development. Future， Hainan Aike Pharmaceutical will rely on its own advantages to control the innovation and development trends of new drugs, with the pharmaceutical industry as the support, implement diversified development, create a comprehensive industry platform, and expand into six major fields: high-end infusion, high-end preparations, innovative drugs, biopharmaceuticals, special medical nutrition agents, and big health. Continuously expanding competitive advantages, enhancing brand influence, continuously improving innovation capabilities, and steadily moving towards an innovative and international pharmaceutical and health industry. Hainan Aike will continue to "love wins brand, technology creates future" Corporate philosophy， Continue to increase research and development investment to achieve sustained and rapid development of the enterprise, and contribute to a healthy China.